Human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) provide
an accessible, genetically tractable, and homogenous starting cell population to efficiently
study human blood cell development. These cell populations provide platforms to develop
new cell-based therapies to treat both malignant and nonmalignant hematological diseases.
Our group previously demonstrated the ability of hESC-derived hematopoietic precursors
to produce functional natural killer (NK) cells as well as an explanation of the underlying
mechanism responsible for the inefficient development of T and B cells from hESCs.
hESCs and iPSCs, which can be engineered reliably in vitro, provide an important new model system to study human lymphocyte development and produce
enhanced cell-based therapies with the potential to serve as a “universal” source
of antitumor lymphocytes. This review will focus on the application of hESC-derived
NK cells with currently used and novel therapeutics for clinical trials, barriers
to translation, and future applications through genetic engineering approaches.
Abbreviations:
ADCC (antibody dependent cellular cytotoxicity), AML (acute myelogenous leukemia), CAR (chimeric antigen receptor), EB (embryoid body), GVHD (graft-versus-host disease), HESC (human embryonic stem cell), HIV (human immunodeficiency virus), HLA (human leukocyte antigen), HSC (hematopoietic stem cell), IFN (interferon), IL-2 (interleukin-2), iPSC (induced pluripotent stem cell), mAb (monoclonal antibody), MHC (major histocompatibility), NK (natural killer), OP9-DL1 (OP9 stroma expressing Delta-like 1), PB=NK (peripheral blood NK), TCR (T-cell receptor), TIL (tumor infiltrating lymphocyte), Treg (T regulatory), UCB (umbilical cord blood)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Translational ResearchAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Bone marrow transplantation: a review.Semin Hematol. 1999; 36: 95-103
- Embryonic stem cell lines derived from human blastocysts.Science. 1998; 282: 1145-1147
- Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury.J Neurosci. 2005; 25: 4694-4705
- Orderly hematopoietic development of induced pluripotent stem cells via Flk-1+ hemoangiogenic progenitors.J Cell Physiol. 2009; 221: 367-377
- Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders.Blood. 2009; 114: 5473-5480
- Hematopoietic and endothelial differentiation of human induced pluripotent stem cells.Stem Cells. 2009; 27: 559-567
- Disease-specific induced pluripotent stem cells.Cell. 2008; 134: 877-886
- Toward clinical therapies utilizing hematopoietic cells derived from human pluripotent stem cells.Blood. 2009; 114: 3513-3523
- Hematopoietic colony-forming cells derived from human embryonic stem cells.Proc Natl Acad Sci U S A. 2001; 98: 10716-10721
- Cytokine requirements differ for stroma and embryoid body-mediated hematopoiesis from human embryonic stem cells.Exp Hematol. 2004; 32: 1000-1009
- Human embryonic stem cell-derived CD34+ cells: efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential.Blood. 2005; 105: 617-626
- Generation of mature human myelomonocytic cells through expansion and differentiation of pluripotent stem cell-derived lin-CD34+CD43+CD45+ progenitors.J Clin Inves. 2009; 119: 2818-2829
- Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity.J Immunol. 2005; 175: 5095-5103
- T lineage differentiation from human embryonic stem cells.Proc Natl Acad Sci U S A. 2006; 103: 11742-11747
- Bioluminescent imaging demonstrates that transplanted human embryonic stem cell-derived CD34+ cells preferentially develop into endothelial cells.Stem Cells. 2009; 27: 2675-2685
- Hematopoietic engraftment of human embryonic stem cell-derived cells is regulated by recipient innate immunity.Stem Cells. 2006; 24: 1370-1380
- Efficient hematopoietic differentiation of human embryonic stem cells on stromal cells derived from hematopoietic niches.Cell Stem Cell. 2008; 3: 85-98
- Human embryonic stem cell-derived hematopoietic cells are capable of engrafting primary as well as secondary fetal sheep recipients.Blood. 2006; 107: 2180-2183
- Generation of hematopoietic repopulating cells from human embryonic stem cells independent of ectopic HOXB4 expression.J Exp Med. 2005; 201: 1603-1614
- Hematopoietic development from human induced pluripotent stem cells.Ann N Y Acad Sci. 2009; 1176: 219-227
- Globin phenotype of erythroid cells derived from human induced pluripotent stem cells.Blood. 2010; 115: 2553-2554
- Generation of induced pluripotent stem cells from human cord blood cells with only two factors: Oct4 and Sox2.Nat Protoc. 2010; 5: 811-820
- Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.Cell. 2006; 126: 663-676
- Induced pluripotent stem cell lines derived from human somatic cells.Science. 2007; 318: 1917-1920
- In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state.Nature. 2007; 448: 318-324
- Reprogramming of human somatic cells to pluripotency with defined factors.Nature. 2008; 451: 141-146
- iPS cells produce viable mice through tetraploid complementation.Nature. 2009; 461: 86-90
- Induction of pluripotent stem cells from adult human fibroblasts by defined factors.Cell. 2007; 131: 861-872
- Human induced pluripotent stem cells free of vector and transgene sequences.Science. 2009; 324: 797-801
- Excision of reprogramming transgenes improves the differentiation potential of iPS cells generated with a single excisable vector.Stem Cells. 2010; 28: 64-74
- Disease-corrected haematopoietic progenitors from Fanconi Anemia induced pluripotent stem cells.Nature. 2009; 460: 53-59
- Differential modeling of Fragile X Syndrome by human embryonic stem cells and induced pluripotent stem cells.Cell Stem Cell. 2010; 6: 407-411
- Generation of iPSCs from cultured human malignant cells.Blood. 2010; 115: 4039-4042
- Generation of pluripotent stem cells from patients with type 1 diabetes.Proc Natl Acad Sci U S A. 2009; 106: 15768-15773
- The habitual, diverse and surmountable obstacles to human immunology research.Nat Immunol. 2008; 9: 575-580
- A prescription for human immunology.Immunity. 2008; 29: 835-838
- Of mice and not men: differences between mouse and human immunology.J Immunol. 2004; 172: 2731-2738
- Human natural killer cells.Blood. 2008; 112: 461-469
- Regulation of NK cell responsiveness to achieve self-tolerance and maximal responses to diseased target cells.Immunol Rev. 2008; 224: 85-97
- Natural killer cell tolerance: licensing and other mechanisms, In Advances in immunology.Academic Press, New York2009 (pp. 27–79)
- Licensing of natural killer cells by self-major histocompatibility complex class I.Immunol Rev. 2006; 214: 143-154
- Human embryonic stem cells differentiate into a unique population of natural killer cells with highly potent in vivo anti-tumor activity.Blood. 2009; 113: 6094-6101
- Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.New Engl J Med. 1988; 320: 1418-1419
- Adoptive cell transfer: a clinical path to effective cancer immunotherapy.Nat Rev Cancer. 2008; 8: 299-308
- Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients.Ann Surg. 1989; 210: 474-485
- Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants.Science. 2002; 295: 2097-2100
- Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.Blood. 2005; 105: 3051-3057
- Prospects for the use of NK cells in immunotherapy of human cancer.Nat Rev Immunol. 2007; 7: 329-339
- Increased infection-related mortality in kir-ligand-mismatched unrelated allogeneic hematopoietic stem-cell transplantation.Transplantation. 2004; 78: 1081-1085
- Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias.Blood. 2005; 105: 2594-2600
- Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors.Blood. 2003; 102: 814-819
- Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.Clin Cancer Res. 2007; 13: 2100-2108
- The role of regulatory T cells in the control of natural killer cells: relevance during tumor progression.Immunol Rev. 2006; 214: 229-238
- Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method.Cancer Gene Therapy. 2010; 17: 147-154
- Forced aggregation of defined numbers of human embryonic stem cells into embryoid bodies fosters robust, reproducible hematopoietic differentiation.Blood. 2005; 106: 1601-1603
- Differentiation of human embryonic stem cells in serum-free medium reveals distinct roles for bone morphogenetic protein 4, vascular endothelial growth factor, stem cell factor, and fibroblast growth factor 2 in hematopoiesis.Stem Cells. 2007; 25: 2206-2214
- Efficient and stable transgene expression in human embryonic stem cells using transposon-mediated gene transfer.Stem Cells. 2007; 25: 2919-2927
- Genetic modification of human embryonic stem cells for derivation of target cells.Cell Stem Cell. 2008; 2: 422-433
- Stable genetic modification of human embryonic stem cells by lentiviral vectors.Mol Ther. 2003; 7: 281-287
- HIV-1 Vpr up-regulates expression of ligands for the activating NKG2D receptor and promotes NK cell-mediated killing.Blood. 2010; 115: 1354-1363
- Human uterine natural killer cells but not blood natural killer cells inhibit human immunodeficiency virus type 1 infection by secretion of CXCL12.J Virol. 2009; 83: 11188-11195
- NK cells in HIV infection: paradigm for protection or targets for ambush.Nat Rev Immunol. 2005; 5: 835-843
- Fifteen years of gene therapy based on chimeric antigen receptors: “are we nearly there yet?”.Hum Gene Ther. 2009; 20: 1229-1239
- Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.Proc Natl Acad Sci U S A. 2009; 106: 3360-3365
- Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.Proc Natl Acad Sci U S A. 2009; 106: 17469-17474
- Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy.J Immunother. 2008; 31: 742-751
- Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells.Cell Stem Cell. 2009; 4: 141-154
- Treatment of chronic lymphocytic leukemia with genetically targeted autologous t cells: case report of an unforeseen adverse event in a phase I clinical trial.Mol Ther. 2010; 18: 666-668
- Case report of a serious adverse event following the administration of t cells transduced with a chimeric antigen receptor recognizing ERBB2.Mol Ther. 2010; 18: 843-851
- Natural killer cell receptor signaling.Curr Opin Immunol. 2003; 15: 308-314
- Expression of cytoplasmic CD3 epsilon proteins in activated human adult natural killer (NK) cells and CD3 gamma, delta, epsilon complexes in fetal NK cells. Implications for the relationship of NK and T lymphocytes.J Immunol. 1992; 149: 1876-1880
- A phase I study on adoptive immunotherapy using gene-modified t cells for ovarian cancer.Clin Cancer Res. 2006; 12: 6106-6115
- Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy.Nat Med. 2010; 16: 565-570
- Monoclonal antibodies: versatile platforms for cancer immunotherapy.Nat Rev Immunol. 2010; 10: 317-327
- Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response.Proc Natl Acad Sci U S A. 2008; 105: 16254-16259
- Differences in lymphocyte developmental potential between human embryonic stem cell and umbilical cord blood-derived hematopoietic progenitor cells.Blood. 2008; 112: 2730-2737
- Induction of T-cell development from human cord blood hematopoietic stem cells by Delta-like 1 in vitro.Blood. 2005; 105: 1431-1439
- Generation of T cells from human embryonic stem cell-derived hematopoietic zones.J Immunol. 2009; 182: 6879-6888
- Supernatural T cells: genetic modification of T cells for cancer therapy.Nat Rev Immunol. 2005; 5: 928-940
Article info
Publication history
Published online: August 05, 2010
Footnotes
Supported by NIH/NHLBIR01 HL77923.
Identification
Copyright
© 2010 Mosby, Inc. Published by Elsevier Inc. All rights reserved.
